Skip to content

Effects of psilocybin therapy on personality structure

David Erritzøe, Leor Roseman, Matthew M. Nour, Keir Maclean, Mendel Kaelen, D.j. Nutt, Robin Carhart-Harris

Acta Psychiatrica Scandinavica June 19, 2018 DOI: 10.1111/acps.12904 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Open-label study Peer reviewed
Sample size 20
Population Patients with moderate or severe, unipolar, treatment-resistant depression
Intervention Psilocybin with psychological support
Dose 10 and 25 mg, one week apart
Duration 3-month follow-up
Topics Psilocybin
Keywords Neuroticism Extraversion and introversion Clinical psychology Agreeableness Personality assessment inventory Hallucinogen
Citations 268
Key points Neuroticism decreased and extraversion increased following psilocybin therapy, with openness also increasing, and these changes were predicted by the degree of insightfulness during the psilocybin session.

Abstract

Objective: To explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment‐resistant depression (TRD).

Method: Twenty patients with moderate or severe, unipolar, TRD received oral psilocybin (10 and 25 mg, one week apart) in a supportive setting. Personality was assessed at baseline and at 3‐month follow‐up using the Revised NEO Personality Inventory ( NEO ‐ PI ‐R), the subjective psilocybin experience with Altered State of Consciousness ( ASC ) scale, and depressive symptoms with QIDS ‐ SR 16.

Results: Neuroticism scores significantly decreased while Extraversion increased following psilocybin therapy. These changes were in the direction of the normative NEO ‐ PI ‐R data and were both predicted, in an exploratory analysis, by the degree of insightfulness experienced during the psilocybin session. Openness scores also significantly increased following psilocybin, whereas Conscientiousness showed trend‐level increases, and Agreeableness did not change.

Conclusion: Our observation of changes in personality measures after psilocybin therapy was mostly consistent with reports of personality change in relation to conventional antidepressant treatment, although the pronounced increases in Extraversion and Openness might constitute an effect more specific to psychedelic therapy. This needs further exploration in future controlled studies, as do the brain mechanisms of postpsychedelic personality change.

Comparable studies

Other non-randomized and open-label trials on psilocybin, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers 2014 Open-label pilot study n = 15
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial

Citations in the library

Cited by 222

and 217 more in the library

Cites 42

and 37 more in the library

Explore topics